Acta Pharmaceutica, Vol. 73 No. 2, 2023.
Original scientific paper
https://doi.org/10.2478/acph-2023-0015
Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro
RUI LIU
; Department of Oncology, South District of Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 102618, China
CUIHONG JIANG
; Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences (South Campus), Beijing 102618, China
ZHIZHENG ZHAO
; Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences (South Campus), Beijing 102618, China
YUTONG LV
; Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences (South Campus), Beijing 102618, China
GAOXING WANG
; Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences (South Campus), Beijing 102618, China
Abstract
This study attempts to explore the function and mechanism of action of rosavin in small-cell lung cancer (SCLC) in vitro. The viability and clone formation of SCLC cells were assessed using cell counting kit-8 and colony formation assays, respectively. Apoptosis and cell cycle were detected using flow cytometry and cell cycle analysis, respectively. Wound healing and transwell assays were performed to evaluate the migration and invasion of SCLC cells. Besides, protein levels of p-ERK, ERK, p-MEK and MEK were determined using western blot analysis. Rosavin repressed the viability and clone formation of SCLC cells, and promoted apoptosis and G0/G1 arrest of SCLC cells. At the same time, rosavin suppressed migration and invasion of SCLC cells. Moreover, protein levels of p-ERK/ERK and p-MEK/MEK were decreased after rosavin addition in SCLC cells. Rosavin impaired malignant behaviors of SCLC cells, which may be associated with inhibition of the MAPK/ERK pathway in vitro.
Keywords
small-cell lung cancer; rosavin; MEK; ERK
Hrčak ID:
286665
URI
Publication date:
30.6.2023.
Visits: 310 *